March 7, 2025 02:57 PM ESTUpdated 04:48 PM
Pharma
FDA+

FDA ap­proves Neu­rotech cell ther­a­py to slow a rare de­gen­er­a­tive eye dis­ease 

Lei Lei Wu

News Reporter

The FDA on Thurs­day ap­proved Neu­rotech Phar­ma­ceu­ti­cals’ cell ther­a­py for an eye dis­ease known as mac­u­lar telang­iec­ta­sia type 2, which caus­es …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Ex­clu­sive: A small biotech will bring Roche's An­gel­man drug back to life

Mer­ck ex­plores po­ten­tial of oral pep­tides in deal with Aus­tri­an biotech

Sid­dhartha Mukher­jee’s cell ther­a­py start­up nar­rows fo­cus as staff shrinks

What's Pfiz­er's next move af­ter shelv­ing its oral obe­si­ty drug danuglipron?

In a blow to its obe­si­ty pipeline, Pfiz­er drops oral drug af­ter liv­er in­jury case

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times